Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bastide Le Confort MedicalLTS:0IP1 -0.43%70 Debt-to-EBITDA is 3.04 as of Dec. 2025, which is 27% below its 10-year median of 4.17. GuruFocus rates LTS:0IP1 with a GF Score™ of 70/100 and a GF Value™ of €25.89 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 90 Medical Distribution companies, Bastide Le Confort Medical ranks worse than 56.67% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bastide Le Confort Medical's Debt-to-EBITDA or its related term are showing as below:
LTS:0IP1'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.22 Med: 4.17 Max: 4.63
Current: 3.08
During the past 13 years, the highest Debt-to-EBITDA Ratio of Bastide Le Confort Medical was 4.63. The lowest was 2.22. And the median was 4.17.
LTS:0IP1's Debt-to-EBITDA is ranked worse than 56.67% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs LTS:0IP1: 3.08
Bastide Le Confort Medical (LTS:0IP1) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bastide Le Confort Medical Debt-to-EBITDA Related Terms
Bastide Le Confort Medical Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IP1 vs MCK, CAH, COR: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Bastide Le Confort Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bastide Le Confort Medical Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Bastide Le Confort Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bastide Le Confort Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Bastide Le Confort Medical (LTS:0IP1) has a Debt-to-EBITDA of 3.04 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bastide Le Confort Medical. This is 27% below median its historical median of 4.17. Over the past decade, Bastide Le Confort Medical's Debt-to-EBITDA has ranged from 2.22 to 4.63. According to the industry distribution chart, Bastide Le Confort Medical ranks #51 out of 90 companies in the Medical Distribution industry, placing it in the top 56.7%.
Is Bastide Le Confort Medical's Debt-to-EBITDA too high?
Bastide Le Confort Medical's current Debt-to-EBITDA of 3.04 is 27% below median its 10-year median of 4.17. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 4.63. The Medical Distribution industry median Debt-to-EBITDA is 2.45. Bastide Le Confort Medical's value of 3.04 is 24.1% above this industry median. Based on the distribution chart, Bastide Le Confort Medical ranks #51 out of 90 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Bastide Le Confort Medical has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bastide Le Confort Medical's Debt-to-EBITDA compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Bastide Le Confort Medical ranks #51 out of 90 companies for Debt-to-EBITDA. This places Bastide Le Confort Medical in the lower half of its industry. The industry median Debt-to-EBITDA is 2.45. Bastide Le Confort Medical's value of 3.04 is 24.1% above this benchmark. Historically, Bastide Le Confort Medical's own Debt-to-EBITDA has ranged from 2.22 to 4.63 over the past decade. While the company's 10-year median is 4.17 vs. the industry median of 2.45, Bastide Le Confort Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bastide Le Confort Medical's current Debt-to-EBITDA of 3.04 is 24.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bastide Le Confort Medical. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bastide Le Confort Medical's current Debt-to-EBITDA is 3.04, which is 27% below median its own 10-year median of 4.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bastide Le Confort Medical stock overvalued right now?
Based on GuruFocus' analysis, Bastide Le Confort Medical (LTS:0IP1) is currently considered Modestly Undervalued. The stock's GF Value™ is €25.89, compared to a current price of €23.20 — trading 10.4% below its estimated fair value. The current Debt-to-EBITDA is 3.04, which is 27% below median its 10-year median of 4.17 and 24.1% above the Medical Distribution industry median of 2.45. Bastide Le Confort Medical's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bastide Le Confort Medical (LTS:0IP1), the current Debt-to-EBITDA is 3.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bastide Le Confort Medical (LTS:0IP1) Overvalued in 2026?
Based on GuruFocus' analysis, Bastide Le Confort Medical stock appears to be undervalued.
The current stock price of €23.20 is trading 10.4% below its estimated GF Value™ of €25.89.
GuruFocus considers Bastide Le Confort Medical to be Modestly Undervalued.
Key valuation signals for LTS:0IP1:
Debt-to-EBITDA: 3.04 (27% below median its 10-year median of 4.17)
GF Value™: €25.89 vs. price of €23.20 (10.4% below fair value)
Industry Position: 24.1% above the Medical Distribution median (#51 of 90)
No single metric tells the full story. See the LTS:0IP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bastide Le Confort Medical SA is a France-based company that is engaged in the sale and rental of medical supplies and equipment for the home care of the elderly, sick and disabled. The company provides care equipment, such as hospital beds, personal assistance products, nutrition, insulin pumps, and syringe-drivers.
70GF Score
Get the complete analysis for LTS:0IP1
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IP1 has been successfully added to your 
